Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Engage: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center Study To Investigate The Efficacy and Safety Of Eliglustat In Adults With Gaucher Disease Type 1: 9 Month Results

Suma Shankar, MD, PhD, Elena Lukina, MD, PhD, Dominick J Amato, MD, Majed Dasouki, MD, Seymour Packman, MD, PhD, Gregory M Pastores, MD, Sarit Assouline, MD, Manisha Balwani, MD, MS, Pramod K Mistry, MD, PhD, FRCP, Leorah H Ross, MD, PhD, Sachin Marulkar, MBBS, MPH, M. Judith Peterschmitt, MD

Blood (2013) 122 (21): 2275.

https://doi.org/10.1182/blood.V122.21.2275.2275

Published: 2013

Journal Articles

Similar 1 Year Survival of Patients Receiving Plerixafor (Mozobil*®) Plus G-CSF Versus Placebo Plus G-CSF Mobilized Autologous Grafts: Results From Two Phase 3 Randomized Trials in Patients with NHL or MM Undergoing Autologous Transplantation After Front-Line or Rescue Mobilization.

Ivana N Micallef, MD, Patrick Stiff, MD, Edward Stadtmauer, MD, Brian J. Bolwell, Sachin Marulkar, MBBS, MPH, Frank J Hsu, MD, John F. DiPersio, MD, PhD

Blood (2009) 114 (22): 2319.

https://doi.org/10.1182/blood.V114.22.2319.2319

Published: 2009

Journal Articles

Plerixafor Plus G-CSF Is An Effective Regimen to Mobilize Hematopoietic Stem Cells in NHL Patients with Circulating Peripheral Blood CD34+ Cells/μl < 10.

Richard T. Maziarz, MD, Ivana N Micallef, MD, Patrick Stiff, MD, Brian J. Bolwell, Sachin Marulkar, MBBS, MPH, Gary C Calandra, M.D., Ph.D., John F. DiPersio, MD, PhD

Blood (2009) 114 (22): 33.

https://doi.org/10.1182/blood.V114.22.33.33

Published: 2009

Journal Articles

Mobilization with Plerixafor (Mozobil ® )Plus G-CSF Results in Superior Day 1 Collection of CD34+ Cells Compared to Placebo Plus G-CSF: Results From Two Randomized Placebo-Controlled Trials in Patients with Multiple Myeloma or Non-Hodgkin's Lymphoma.

Brian J. Bolwell, Auayporn P. Nademanee, MD, Patrick Stiff, MD, Edward Stadtmauer, MD, Richard T. Maziarz, MD, Ivana N Micallef, MD, Sachin Marulkar, MBBS, MPH, Pritesh Gandhi, PharmD, John F. DiPersio, MD, PhD

Blood (2009) 114 (22): 3224.

https://doi.org/10.1182/blood.V114.22.3224.3224

Published: 2009

Journal Articles

Plerixafor (Mozobil ® )Plus G-CSF Is Effective in Mobilizing Hematopoietic Stem Cells in Patients with Concurrent Thrombocytopenia Undergoing Autologous Hematopoietic Stem Cell Transplantation.

Ivana N Micallef, MD, Eric Jacobsen, Paul Shaughnessy, MD, Sachin Marulkar, MBBS, MPH, Purvi Mody, PhD, Frits van Rhee, MD, PhD

Blood (2009) 114 (22): 3229.

https://doi.org/10.1182/blood.V114.22.3229.3229

Published: 2009

Journal Articles

Plerixafor (Mozobi ® )Plus G-CSF Is More Effective Than Placebo Plus G-CSF in Mobilizing CD34+ Hematopoietic Stem Cells in Patients with Multiple Myeloma Who Have Low (<20 cells/μl) Peripheral Blood CD34+ Cell Count.

Auayporn P. Nademanee, MD, Edward Stadtmauer, MD, Ivana N Micallef, MD, Patrick Stiff, MD, Sachin Marulkar, MBBS, MPH, Gary C Calandra, M.D., Ph.D., John F. DiPersio, MD, PhD

Blood (2009) 114 (22): 3230.

https://doi.org/10.1182/blood.V114.22.3230.3230

Published: 2009

NARROW

Engage: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center Study To Investigate The Efficacy and Safety Of Eliglustat In Adults With Gaucher Disease Type 1: 9 Month Results

Similar 1 Year Survival of Patients Receiving Plerixafor (Mozobil*®) Plus G-CSF Versus Placebo Plus G-CSF Mobilized Autologous Grafts: Results From Two Phase 3 Randomized Trials in Patients with NHL or MM Undergoing Autologous Transplantation After Front-Line or Rescue Mobilization.

Plerixafor Plus G-CSF Is An Effective Regimen to Mobilize Hematopoietic Stem Cells in NHL Patients with Circulating Peripheral Blood CD34+ Cells/μl < 10.

Mobilization with Plerixafor (Mozobil ® )Plus G-CSF Results in Superior Day 1 Collection of CD34+ Cells Compared to Placebo Plus G-CSF: Results From Two Randomized Placebo-Controlled Trials in Patients with Multiple Myeloma or Non-Hodgkin's Lymphoma.

Plerixafor (Mozobil ® )Plus G-CSF Is Effective in Mobilizing Hematopoietic Stem Cells in Patients with Concurrent Thrombocytopenia Undergoing Autologous Hematopoietic Stem Cell Transplantation.

Plerixafor (Mozobi ® )Plus G-CSF Is More Effective Than Placebo Plus G-CSF in Mobilizing CD34+ Hematopoietic Stem Cells in Patients with Multiple Myeloma Who Have Low (<20 cells/μl) Peripheral Blood CD34+ Cell Count.

Email alerts

ASH Publications

American Society of Hematology

Engage: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center Study To Investigate The Efficacy and Safety Of Eliglustat In Adults With Gaucher Disease Type 1: 9 Month Results

Similar 1 Year Survival of Patients Receiving Plerixafor (Mozobil*®) Plus G-CSF Versus Placebo Plus G-CSF Mobilized Autologous Grafts: Results From Two Phase 3 Randomized Trials in Patients with NHL or MM Undergoing Autologous Transplantation After Front-Line or Rescue Mobilization.

Plerixafor Plus G-CSF Is An Effective Regimen to Mobilize Hematopoietic Stem Cells in NHL Patients with Circulating Peripheral Blood CD34+ Cells/μl < 10.

Mobilization with Plerixafor (Mozobil ® )Plus G-CSF Results in Superior Day 1 Collection of CD34+ Cells Compared to Placebo Plus G-CSF: Results From Two Randomized Placebo-Controlled Trials in Patients with Multiple Myeloma or Non-Hodgkin's Lymphoma.

Plerixafor (Mozobil ® )Plus G-CSF Is Effective in Mobilizing Hematopoietic Stem Cells in Patients with Concurrent Thrombocytopenia Undergoing Autologous Hematopoietic Stem Cell Transplantation.

Plerixafor (Mozobi ® )Plus G-CSF Is More Effective Than Placebo Plus G-CSF in Mobilizing CD34+ Hematopoietic Stem Cells in Patients with Multiple Myeloma Who Have Low (<20 cells/μl) Peripheral Blood CD34+ Cell Count.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only